← All trials
NCT05400122
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 9, 2022
- Primary completion
- Jun 1, 2023
- Completion date
- Dec 1, 2023
- First posted
- Jun 1, 2022
- Last posted
- Dec 1, 2022
- Enrollment
- 12
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Case Western Reserve UniversityLead sponsor
- Case Western Reserve UniversityOverall official - principal investigator
- Case Western Reserve UniversitySponsor investigator
Drugs studied
Indications studied
- Esophageal Neoplasms
- Hodgkin Disease
- Lymphoma, Non-Hodgkin
- Multiple Myeloma
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Rectal Neoplasms
- Stomach Neoplasms
- Colorectal Neoplasms
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid, Acute
- Hematologic Neoplasms
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.